Comparative Pharmacology
Head-to-head clinical analysis: ILUVIEN versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILUVIEN versus SYNACORT.
ILUVIEN vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluocinolone acetonide, a corticosteroid, suppresses inflammation by inhibiting phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis. It also inhibits cytokine production and endothelial cell adhesion molecule expression.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
Intravitreal implant containing 0.19 mg fluocinolone acetonide, designed to release drug over approximately 36 months. Administered as a single injection into the vitreous cavity of the eye.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Intravitreal terminal half-life of fluocinolone acetonide from the Iluvien implant is approximately 30 months (range 18-36 months), providing sustained release over 36 months in the vitreous cavity.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Fluocinolone acetonide is primarily eliminated via hepatic metabolism and subsequent fecal/biliary excretion. Approximately 50-70% of a dose is excreted in feces as metabolites, with less than 20% recovered in urine as unchanged drug or metabolites.
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid